Groundbreaking ceremony for SHL Medical’s new site in Taiwan
SHL Medical, a pioneering leader in self-injection solutions, has announced the construction of its new manufacturing site in Taoyuan, Taiwan (hereafter referred to as Taoyuan-Nanmei site). The project marks the continued collaboration between SHL Medical and Great Honor Asset Management. On July 3rd, General Manager of SHL Medical Taiwan, Sebastian Feng, along with the management team, the Great Honor Asset Management team, and Nanmei and Nanshang community leaders Ya-Jung Huang and Ting-Ching Chen gathered for this memorable groundbreaking event.
The new Taoyuan-Nanmei site marks a significant milestone in SHL Medical’s journey in Taiwan. Established in Taoyuan in 1989, SHL now has over 5,000 employees worldwide and has become a key partner for pharma and biotech industries. With a global presence spanning across three continents, SHL has continued to expand its operations in Taiwan over the past 35 years, growing to nine sites by 2019.
SHL’s new site is slated for completion in 2027. The seven-story building will cover a total floor area of 47,000 square meters and will be equipped with key manufacturing capabilities. By integrating existing facilities, SHL will optimize transportation and logistics while reducing carbon footprints. In line with SHL’s sustainability strategy, the new site will incorporate green energy and solar panels, further reinforcing the company’s commitment to sustainability. Additionally, the upgraded office facilities at the new site will provide an enhanced working environment for employees, demonstrating the company’s dedication to employee wellbeing.
“As SHL Medical continues to grow, we remain committed to optimizing our operations and strengthening our global market leadership,” said Sebastian Feng. “The new Taoyuan-Nanmei site will consolidate parts of our existing resources in Taiwan, allowing us to streamline our operations.”
To support pharma and biotech partners in enabling patients’ independence, SHL Medical provides end-to-end solutions from design, molding, tooling, automated assembly, testing, to validation under one roof. Over the next five years, SHL Medical will invest US$100 million to streamline processes by integrating capabilities and upgrading its Taiwan facilities. In the coming years, SHL Medical will continue to foster local professionals, driving growth both locally and globally.
“We highly value our contribution to the local community,” emphasized SHL Medical CEO Ulrich Faessler. “The establishment of the new site further strengthens our commitment to providing best-in-class services and advancing Taiwan’s medtech industry.”
